STORM in the News
Drug Hunter: Targeting Post-Transcriptional RNA-Modification with a First-to-Clinic METTL3 Inhibitor: STC15
STC15 is Storm Therapeutics' first-in-class, and first-to-clinic inhibitor of the post-transcriptional RNA modifier METTL3, which progressed from HTS hit to clinical development in less than three years. Targeting RNA has been of significant recent interest, catalyzed in part by the clinical success of small-molecule RNA splicing modifiers.
Read more